Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 9, 2001, Pages 2604-2608

  Kenny, G E ^a   Cartwright, F D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN; EVERNIMICIN; GATIFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; QUINOLONE DERIVATIVE; QUINUPRISTIN; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA HOMINIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL;

4-QUINOLONES; ACETAMIDES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; ERYTHROMYCIN; FLUOROQUINOLONES; HUMANS; HYDROGEN-ION CONCENTRATION; KETOLIDES; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MYCOPLASMA HOMINIS; MYCOPLASMA PNEUMONIAE; OXAZOLIDINONES; QUINOLINES; TETRACYCLINES; UREAPLASMA UREALYTICUM; VIRGINIAMYCIN;

EID: 0034863518     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.9.2604-2608.2001     Document Type: Article

References (33)

1. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae
2. A review of the in-vitro activity of quinupristin-dalfopristin against intracellular pathogens and mycoplasmas
3. Determination of minimal inhibitory concentration
4. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas
5. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis
6. Efficacy of clarithromycin against Mycoplasma pneumoniae
7. Evernimicin (SCH 27899) inhibits both translation and 50S ribosomal subunit formation in Staphylococcus aureus cells
8. Comparative susceptibilities of various AIDS-associated and human genital tract mycoplasmas and strains of Mycoplasma pneumoniae to 10 classes of antimicrobial agent in vitro
9. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae
10. In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 1069072 against Mycoplasma pneumoniae
11. Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro
12. Mycoplasmas
13. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin
14. Effect of pH, inoculum size and incubation time on the susceptibility of Ureaplasma urealyticum to erythromycin in vitro
15. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines
16. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method
17. Human respiratory tract infection with mycoplasmas and their in vitro susceptibility to tetracyclines and some other antibiotics
18. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics
19. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylgycylamido derivative of minocycline (GAR-936)
20. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin, and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum
21. In vitro activity of dirithromycin, a new macrolide antibiotic against Mycoplasma species
22. Effects of environmental factors on the in vitro potency of azithromycin
23. Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum
24. Tetracycline-resistant Mycoplasma hominis strains contain tetM sequences
25. In vitro comparison of the activity of doxycycline, tetracycline, erythromycin, and a new macrolide, CP 62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum
26. Enhancing effect on alkalinization of the medium on the activity of erythromycin against Gram-negative bacteria
27. Comparative in vitro sensitivity of Mycoplasma pneumoniae to rosaramicin, erythromycin, tetracycline and spectinomycin
28. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
29. The effect of antibiotics on Mycoplasma pneumoniae in vitro and in vivo
30. Resistance of Mycoplasma pneumoniae to macrolides, lincomycin, and streptogramin B
31. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones
32. In vitro a activity of telithromycin (HMR 3647), a new ketolide, against clinical isolates of Mvcoplasma pneumoniae in Japan